{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.58","value":"5.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"Ibrutinib: Pre-dose Day 1 Cycle 2 (Ibrutinib Alone)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.78","value":"6.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"title":"Ibrutinib: Pre-dose Day 1 Cycle 3 (Ibrutinib Alone)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.71","value":"6.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Ibrutinib: Pre-dose Day 1 Cycle 5 (Ibrutinib and Venetoclax)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.74","value":"5.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Ibrutinib: Pre-dose Day 1 Cycle 6 (Ibrutinib and Venetoclax)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"959","value":"1139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"title":"Venetoclax: Pre-dose Day 1 Cycle 5 (Ibrutinib + Venetoclax)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1573","value":"1765"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Venetoclax: Pre-dose Day 1 Cycle 6 (Ibrutinib + Venetoclax)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Plasma concentrations of ibrutinib and venetoclax were determined by validated liquid chromatography-tandem mass spectrometry.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment Arm A (Ibrutinib + Venetoclax)"}],"paramType":"MEAN","populationDescription":"The pharmacokinetics (PK) analysis set is defined as all randomized participants in Treatment Arm A who received at least one dose of ibrutinib and/or venetoclax and had at least one valid blood sample drawn for PK analysis. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this endpoint. Here, \"n (number analyzed)\" is defined as number of participants analyzed for specified category.","reportingStatus":"POSTED","timeFrame":"Ibrutinib: Pre-dose-Day 1 of Cycles 2, 3, 5 and 6 (each cycle is defined as 28 days), Venetoclax: Pre-dose-Day 1 of Cycles 5 and 6","title":"Plasma Concentration of Ibrutinib and Venetoclax","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter (ng/mL)"}